Depressive Syndrome
Conditions
Keywords
Osteoporosis, Raloxifene, Central nervous disorders
Brief summary
The study will be conducted to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.
Detailed description
Fracture is one of the important complications in female. Osteoporosis should be treated in postmenopausal female due to high risk of fracture. Recently, there have been many classes of medications developed for preventing bone loss. Raloxifene, an oral form of anti-osteoporosis medication, has been reported to improved central nervous disorders. Therefore, this study is designed to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.
Interventions
DRUGRaloxifene
Raloxifene tratment more than 4 weeks
DRUGAlendronate
Alendronic acid 70mg with Colecalciferol 70mcg
Sponsors
Taichung Veterans General Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Postmenopausal female * Osteoporosis
Exclusion criteria
* Psychological disorders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Brain-derived neurotrophic factor | 3 months | Serum brain-derived neurotrophic factor (BDNF) Levels |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Orexin-A | 3 months | Serum Orexin-A levels |
| Body components | 3 months | Fat tissue ratio |
| Zung self-rating depression scale | 3 months | Questionnaire for depressive symptoms |
| 5-Item Geriatric Depression Scale | 3 months | Questionnaire for Cognitive assessment |
| Vascular cell adhesion molecule-1 | 3 months | Serum vascular cell adhesion molecule-1 (VCAM-1) levels |
| The Barthel index | 3 months | Questionnaire for Cognitive assessment |
| Instrumental Activities of Daily Living (IADL) | 3 months | Questionnaire for Cognitive assessment |
| ankle-brachial index | 3 months | Peripheral artery disease assessment |
| Brain-derived neurotrophic factor | 1 year | Serum brain-derived neurotrophic factor (BDNF) Levels |
| The Mini Mental State Examination (MMSE) | 3 months | Questionnaire for Cognitive assessment |
Countries
Taiwan
Contacts
Primary ContactI-Te Lee, MD, PhD
Backup ContactI-Te Lee, MD, PhD
Outcome results
None listed